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Abstract
Background: Cigarette smoking is an established risk factor for bladder cancer. Epidemiological
and biological data suggest that genetic polymorphisms in activating and detoxifying enzymes may
play a role in determining an individual's susceptibility to bladder cancer in particular when in
combination with specific environmental exposures such as cigarette smoking. N-acetyltransferase
(NAT) enzymes, NAT1 and NAT2, are involved in the activation and detoxification of tobacco
smoke constituents. Polymorphisms in these genes alter the ability of these enzymes to metabolize
carcinogens, as certain allelic combinations result in a slow or rapid acetylation phenotype.
Glutathione S-transferases (GSTs) also detoxify tobacco smoke constituents, and polymorphisms
within the GSTM1 and GSTT1 genes can result in a complete lack of enzyme activity.
Methods: We assessed the association between common polymorphisms identified in the GSTM1,
GSTT1, NAT1, and NAT2 genes and the risk of bladder cancer in two nested case-control studies
within the Nurses' Health Study (n = 78 female cases, 234 female controls) and the Health
Professionals' Follow-up Study (n = 139 male cases, 293 male controls). We also evaluated whether
cigarette smoking modified the associations of the genotypes and bladder cancer risk in men and
women.
Results: Overall, we observed no statistically significant associations between the polymorphisms
and bladder cancer risk among men and women, although given our sample size, we had limited
power to detect small to moderate effects. There was however the suggestion of an increased risk
among female ever smokers with the NAT2 slow genotype and an increased risk in male never
smokers with the GSTM1 null genotype.
Conclusion:  In summary, these prospective results are consistent with previous literature
supporting associations between bladder cancer and the NAT2 slow acetylation and the GSTM1 null
genotypes.
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Background
Cigarette smoking is the predominant risk factor for blad-
der cancer in males and females [1-5]. Carcinogens such
as aminobiphenyls (ABPs) found in tobacco have been
implicated in bladder cancer etiology in smokers [6]. N-
acetyltransferase (NAT) enzymes, NAT1 and NAT2, are
involved in the metabolism of these carcinogens via O-
and N- acetylation [7]. NAT2 and NAT1 are involved in
the detoxification and bioactivation of carcinogens [8,9].
Four major NAT1 alleles, NAT1*3, NAT1*4, NAT1*10,
NAT*11 [10], and three common NAT2 alleles, NAT2*5,
NAT2*6, NAT2*7, have been identified in Caucasian pop-
ulations [7]. Individuals homozygous for NAT2  rapid
acetylator alleles are classified as rapid-acetylator pheno-
type; individuals homozygous for NAT2 slow acetylator
alleles are classified as slow-acetylator phenotype, and
heterozygous individuals (one rapid and one slow
acetylator alleles) are classified as the intermediate pheno-
type [11]. The slow NAT2 acetylation genotype compro-
mises its detoxification ability, and studies have
consistently observed an association between the slow
NAT2 genotype and increased bladder cancer risk [11-13].
The presence of one copy of the NAT1*10 allele has been
associated with a rapid phenotype [8,10] however a more
recent study does not support these earlier findings [14].
Several studies have investigated the association between
the  NAT1  variant alleles and bladder cancer risk with
inconsistent results [14-20]. Fewer studies however have
formally evaluated whether the relationship of cigarette
smoking and bladder cancer risk differed by acetylation
status [11,16,18-20].
Glutathione S-transferases (GSTs) are involved in the
metabolism of environmental carcinogens, reactive oxy-
gen species, and chemotherapeutic agents by catalyzing
reactions between glutathione and electrophilic com-
pounds [21,22]. Glutathione S-transferase M1 (GSTM1) is
involved in the detoxification of polycyclic aromatic
hydrocarbons (PAHs) and benzo(a)pyrene found in
tobacco smoke [23,24]. Glutathione S-transferase T1
(GSTT1) is involved in activation and detoxification reac-
tions and catalyzes the conjugation of industrial chemi-
cals,  e.g.  ethylene oxides, with glutathione [25].
Homozygous deletions of the GSTM1 and GSTT1 genes
are common and result in a complete loss of enzyme
activity [22,26,27]. Because the metabolism of tobacco-
related carcinogens may be influenced by the activity of
GSTs, polymorphisms in GSTM1 and GSTT1 may modify
the risk of bladder cancer associated with these carcino-
gens. The GSTM1 null polymorphism has been consist-
ently associated with an increased risk of bladder cancer in
pooled and meta-analyses [11,23,28]. Studies investigat-
ing the importance of GSTT1 in bladder carcinogenesis
are more limited and inconsistent [19,24,29-35].
Since exposure to tobacco smoke carcinogens is a risk fac-
tor for bladder cancer, genetic modulation of carcinogen
metabolism may explain some inter-individual bladder
cancer susceptibility. Given their biological role, polymor-
phisms within the GSTT1,  GSTM1,  NAT1, and NAT2
genes may be important in determining an individual's
susceptibility to bladder cancer. Recent studies have also
suggested that although the risk associated with each var-
iant may be small, in combination with other genetic and/
or environmental factors, the effects of the polymor-
phisms may be increased. We examined the associations
between polymorphisms within these key genes and blad-
der cancer risk in a nested case-control study of women
participating in the Nurses' Health Study (NHS) and a
nested case-control study of men participating in the
Health Professionals' Follow-Up Study (HPFS). Further-
more, we assessed the potential for effect modification by
cigarette smoking for the associations between the geno-
types and bladder cancer risk.
Methods
Nurses' Health Study
The NHS began in 1976 when 121,700 female United
States registered nurses aged 30–55 years completed a self-
administered questionnaire. Detailed information on
individual characteristics and behaviors was obtained
from the questionnaires at baseline and biennially there-
after. Between 1989 and 1990, blood samples were col-
lected from 32,826 women; follow-up for this subcohort
exceeds 96%. The methods used for blood collection have
been previously detailed [36].
Case-control study
In our study, we included both incident and prevalent
bladder cancer cases from the NHS blood cohort. Trained
physicians who were blinded to exposure information
reviewed hospital records and pathology reports. We were
able to confirm approximately 95% of self-reported blad-
der cancer cases. Eligible incident cases consisted of
women with confirmed bladder cancer that had been
diagnosed anytime after blood collection (1989–90) and
up to June 1, 2000, with no previously diagnosed cancer
except for nonmelanoma skin cancer. Prevalent cases were
defined as having confirmed bladder cancer diagnosed
after questionnaire return in 1976 and before the date of
blood collection, with no previously diagnosed cancer
except for nonmelanoma skin cancer. Controls were ran-
domly selected participants who had given a blood sam-
ple and were free of diagnosed cancer (except
nonmelanoma skin cancer) up to and including the inter-
val in which the case was diagnosed. Controls were
matched to cases 3:1 according to year of birth, smoking
status at blood draw (never versus ever), month of blood
collection, and fasting status at blood draw (for possible
plasma hormone analyses). This case-control study con-BMC Cancer 2006, 6:239 http://www.biomedcentral.com/1471-2407/6/239
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sists of 78 bladder cancer cases (47 incident cases and 31
prevalent cases), and 234 matched controls. In addition,
2646 women who were controls in either a nested case-
control study of breast cancer (n = 1686) [37,38], colon
cancer (n = 461) [39], and colon polyps (n = 499), were
free of cancer other than nonmelanoma skin cancer, and
were genotyped for the three NAT2 polymorphisms were
included in unconditional logistic regression analyses to
stabilize confidence intervals. A subset of the extra con-
trols (n = 466) from the breast cancer nested case-control
study [40] were genotyped for the GSTM1 and GSTT1 pol-
ymorphisms and included in the unconditional logistic
regression analyses. The study protocol was approved by
the Committee on Use of Human Subjects of the Brigham
and Women's Hospital, Boston, MA. Completion of the
self-administered questionnaire and receipt of the blood
sample were considered to imply informed consent.
Health professionals' follow-up study
The HPFS is an ongoing prospective study of the causes of
chronic diseases in men. The cohort began in 1986 when
51,529 U.S. male health professionals aged 40 to 75 years
responded to a mailed questionnaire [41]. These men pro-
vided detailed information on medical histories and
health-related exposures at baseline and biennial ques-
tionnaires thereafter. The follow-up for these participants
is approximately 93%. Blood samples were collected
between 1993 and 1995 from 18,025 participants.
Approximately 95% of the samples arrived within 24
hours of blood draw.
Case-control study
In our study, we included both incident and prevalent
bladder cancer cases from the HPFS blood cohort. All
cases in this analysis were confirmed through histopatho-
logic reports reviewed by a study investigator. Eligible
incident cases consisted of men with confirmed bladder
cancer that had been diagnosed anytime after blood col-
lection (1993–95) and up to June 1, 2000, with no previ-
ously diagnosed cancer except for nonmelanoma skin
cancer. Prevalent cases were defined as having confirmed
bladder cancer diagnosed after questionnaire return in
1986 and before the date of blood collection, with no pre-
viously diagnosed cancer except for nonmelanoma skin
cancer. All controls were randomly selected participants
who had given a blood sample and were free of diagnosed
cancer (except nonmelanoma skin cancer) up to and
including the interval in which the case was diagnosed.
Controls were matched to cases 2:1 according to year of
birth, smoking status at blood draw (current, past, or
never), fasting status (for possible plasma hormone anal-
yses), and month of sample collection. For cases accrued
from 1998 to 2000, controls were matched to cases 3:1
with the previously described matching factors to increase
our statistical power. This case-control study consists of
139 bladder cancer cases (91 incident cases and 48 preva-
lent cases), and 293 matched controls. In addition, 1028
men who were controls in either a nested case-control
study of colon cancer (n = 321) or colon polyps (n = 707),
were free of cancer other than nonmelanoma skin cancer,
and were also genotyped for the three NAT2 polymor-
phisms were included in unconditional logistic regression
analyses. Completion of the self-administered question-
naire and receipt of the blood sample were considered to
imply informed consent.
Sample collection
Venous blood samples were separated into plasma, buffy
coat, and red blood cells and stored in liquid nitrogen.
Genomic DNA was extracted from 50 μL buffy coat
diluted with 150 μL of PBS using the QIAGEN QIAmp
(Qiagen, Inc., Chatsworth, CA) 96-spin blood protocol
according to the manufacturer's instructions. Genomic
DNA concentrations were calculated in 96-well format
using PicoGreen technology (Molecular Probes, Eugene,
OR).
Genotyping methods
Genotyping was performed at the DFCI/Harvard Cancer
Center High Throughput Genotyping Core. The NAT2
I114T  (NAT2*5A),  R197Q  (NAT2*6A), and G286E
(NAT2*7A) polymorphisms were genotyped by the 5'
nuclease assay (Taqman) on the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA). A description of and methods for each NAT2
assay can be found at the National Cancer Institute
SNP500Cancer website [42]. We did not genotype poly-
morphisms that are rare (defined as < 5% frequency) in
Caucasian populations [7], such as the NAT2*14 allele
(G191A) [43]. For consistency with previous studies, par-
ticipants were classified as slow NAT2 acetylators if they
were homozygous for any combination of the three slow
acetylators (NAT2*5A, NAT2*6A, NAT2*7A)[11]. Rapid
acetylators for NAT2 were defined as being either hetero-
zygous or homozygous for the wildtype NAT2*4 allele.
We genotyped four common NAT1  alleles,  NAT1*3
(C1095A), NAT1*4 (wildtype), NAT1*10 (C1095A and
T1088A), NAT1*14 (G560A, T1088A ,and C1095A), and
NAT1*11  (deletion of nine nucleotides from 1080 to
1088) [15,44]. The NAT1*4 allele is the most common
allele in all populations studied, and the homozygous
NAT1*4 genotype has been associated with normal NAT1
acetylation activity [7]. The NAT1*10 allele is considered
the putative rapid allele in comparison with NAT1*3,
NAT1*4, NAT1*11, and NAT1*14 [10]. All individuals
with the NAT1*10  genotype were classified as either
homozygous or heterozygous rapid acetylators.BMC Cancer 2006, 6:239 http://www.biomedcentral.com/1471-2407/6/239
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Genotypes for the GSTT1  and  GSTM1  deletions were
determined by polymerase chain reaction (PCR) using a
previously published protocol [40]. In both assays, the
absence of the PCR product was indicative of the null gen-
otype; these assays do not distinguish between hetero-
zygous or homozygous wildtype genotypes.
All genotyping was performed by laboratory personnel
blinded to case-control status, and blinded quality control
samples were inserted to validate genotyping identifica-
tion procedures; concordance for blinded samples was
100%.
Statistical analysis
We used a χ2 test to assess whether the genotypes were in
Hardy-Weinberg equilibrium and to determine P values
for differences in genotype frequencies between cases and
controls. The associations between the genotypes and
bladder cancer risk were examined by using conditional
and unconditional logistic regression to calculate odds
ratios (ORs) and 95% confidence intervals (CIs). Uncon-
ditional logistic regression models assessing the main
effect of the genotype on bladder cancer risk included the
additional control groups to maximize the sample size,
stabilize CIs, and to increase the power to detect meaning-
ful associations. In addition to the matching factors, anal-
yses were also adjusted for packyears of smoking (i.e.
average reported number of cigarette packs smoked per
day multiplied by the number of years of smoking). Inclu-
sion of additional factors, e.g. geographic region, alcohol
intake, cruciferous vegetable intake, did not substantially
change the point estimates, and therefore these factors
were not included in the final models. To test statistical
interactions between the genotypes and cigarette smoking
in unconditional models, we first used a likelihood-ratio
test (LRT) to compare nested models that included terms
for all combinations of the genotypes and cigarette smok-
ing status to the models with indicator variables for the
main effects only (nominal LRT). To test the statistical
interaction between the various genotypes, a similar
approach was employed. All p-values are two-sided. We
used the SAS Version 8.2 software (SAS Institute, Cary,
NC). Because the allele frequencies of NAT1,  NAT2,
GSTM1, and GSTT1 differ by ethnicity [7,23,24,45,46], all
analyses were restricted to Caucasians. Numbers may vary
for the different analyses due to missing genotype data.
We had 80% power to detect the following ORs for the
men: OR = 1.8 for the GSTM1 null genotype assuming a
genotype prevalence of 50%; OR = 2.0 for the GSTT1 null
genotype assuming a genotype prevalence of 15%; OR =
1.9 for the NAT2 slow acetylation genotype assuming a
genotype prevalence of 62%; OR = 1.8 for the NAT1*10
carrier assuming a genotype prevalence of 35%. We had
80% power to detect the following ORs for the women:
OR = 2.1 for the GSTM1 null genotype assuming a geno-
type prevalence of 50%; OR = 2.4 for the GSTT1 null gen-
otype assuming a genotype prevalence of 15%; OR = 2.3
for the NAT2 slow acetylation genotype assuming a geno-
type prevalence of 62%; OR = 2.1 for the NAT1*10 carrier
assuming a genotype prevalence of 35%.
Results
Population characteristics
Our study population included 78 bladder cancer cases
and 234 matched controls from the NHS and 139 bladder
cancer cases and 293 matched controls from the HPFS for
a total of 217 bladder cancer cases and 526 matched con-
trols. The risk factor profile for female bladder cancer
cases and controls were similar with no statistically signif-
icant differences between cases and controls (Table 1).
Similarly, no significant differences in risk factor distribu-
tions were observed in cases and controls in the HPFS
(Table 1). Risk factor distributions between incident and
prevalent cases in the NHS and incident and prevalent
cases in the HPFS were also similar. A comparison of the
population characteristics of the second control group
with the first control group revealed no material differ-
ences in risk factor profiles in the NHS and HPFS.
We compared the distributions of the GSTM1,  GSTT1,
NAT1, and NAT2 genotypes between incident and preva-
lent bladder cancer cases in men and women separately to
determine whether the variant alleles were associated with
survival. All of the genotype frequencies were similar
among incident and prevalent cases in the NHS and in the
HPFS (p > 0.2). Therefore, all incident and prevalent cases
in each cohort were combined to form one case group for
all statistical analyses. The genotype frequencies were in
Hardy-Weinberg equilibrium for cases and controls. The
allele frequencies among the controls for the GSTM1 null
allele, GSTT1 null allele, NAT2 rapid genotype, and the
NAT1  rapid genotype were similar to previously pub-
lished reports in Caucasians [10,18,23,26,38,46,47].
Results from the conditional logistic regression analyses
using only the matched dataset were similar to the results
obtained from the unconditional analyses that included
the additional controls.
Nurses' Health Study
In the NHS, the prevalence of GSTM1 null genotype was
similar among cases and controls (48.4% versus 52.5%,
respectively, p = 0.54), in contrast to the GSTT1 null gen-
otype, which was more prevalent in cases than controls
(21.9% vs. 15.2%, respectively, p = 0.16). After adjusting
for the matching factors and packyears of smoking, we
observed no association between the GSTM1 and GSTT1
polymorphisms and bladder cancer risk in women (Table
2). We did not observe any statistically significant effect
modification by cigarette smoking status for the GSTM1
and the GSTT1 null genotypes and bladder cancer risk (pBMC Cancer 2006, 6:239 http://www.biomedcentral.com/1471-2407/6/239
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for interaction > 0.30). Our results also do not support a
gene-gene interaction between the GSTT1  and  GSTM1
polymorphisms (p for interaction = 0.88).
The frequency of the NAT2 slow acetylation genotype was
similar among cases and controls (68.3% versus 62.1%,
respectively, p = 0.32) (Table 3). The adjusted OR for the
slow acetylation genotype compared to the rapid acetyla-
tion genotype was 1.33 (95% CI, 0.77–2.31). After strati-
fication by cigarette smoking status, the association
between  NAT2  slow acetylation genotype and bladder
cancer risk was stronger but not statistically significant
among ever smokers (OR = 1.76; 95% CI, 0.88–3.52) (p
for interaction = 0.15). We observed no significant associ-
ation between bladder cancer risk and individuals carry-
ing the NAT1*10  allele (Table 3), and no effect
modification by cigarette smoking status for the NAT1
genotypes and bladder cancer risk (p for interaction >
0.10).
Health professionals' follow-up study
There were no significant differences in GSTM1  and
GSTT1 genotype frequencies among cases and controls (p
= 0.09 and 0.63, respectively), and no statistically signifi-
cant associations between the GSTM1 and GSTT1 poly-
morphisms and bladder cancer risk in males (Table 2). We
did observe a statistically significant interaction between
the GSTM1 null genotype, cigarette smoking, and bladder
cancer risk in males (p for interaction = 0.02). Among
never smokers, the GSTM1 null genotype was associated
with a statistically significant increased risk (OR = 3.23
(95% CI, 1.38, 7.58)), and among ever smokers, the OR
was 0.96 (95% CI, 0.55–1.66). The association between
GSTT1 polymorphism and bladder cancer risk remained
similar after stratification by smoking status (p for interac-
tion = 0.69), and no significant gene-gene interactions
with GSTM1 and GSTT1 were detected (p for interaction =
0.22).
The frequency of the NAT2 slow acetylation genotype was
similar among cases and controls (57.3% versus 61.8%, p
= 0.32) (Table 3). The adjusted OR for the slow acetyla-
tion genotype compared to the rapid acetylation genotype
was 0.78 (95% CI, 0.53–1.15). We observed no signifi-
cant association between bladder cancer risk and carrying
the NAT1*10 allele (Table 3). Furthermore, we did not
observe any statistically significant effect modification by
cigarette smoking status for the NAT2 or NAT1 genotypes
and bladder cancer risk (p for interaction > 0.4).
Discussion
Evidence suggests that polymorphisms in activating and
detoxifying enzymes may interact to effect the level of
DNA damage sustained by a specific tissue and ultimately
influence disease risk [47]. Therefore, imbalances between
activation and detoxification processes may result in an
increase in bladder cancer risk due to the accumulation of
carcinogen metabolites, e.g. from cigarette smoking. Over-
all, in our population-based case-control study, we
observed no statistically significant associations between
the  GSTT1,  GSTM1,  NAT1, and NAT2  polymorphisms
and bladder cancer risk.
Aromatic amines within tobacco smoke are the most
important class of bladder carcinogens [48]. These com-
pounds may be partially responsible for the increased
Table 1: Selected population characteristics of bladder cancer cases and matched controls
Variable NHS HPFS
Cases (n = 78) Controls 
(n = 234)
P-value Cases (n = 139) Controls 
(n = 293)
P-value
Age at diagnosis (years),1 mean (SD) 60.6 (9.2) 60.6 (9.2) > 0.99 68.5 (8.6) 68.6 (8.6) 0.87
BMI at diagnosis (kg), mean (SD) 22.0 (9.7) 23.8 (8.6) 0.13 25.8 (2.8) 25.5 (3.2) 0.45
Ethnicity/ancestry, n (%) 0.67 0.56
Caucasian 65 (90.3) 210 (93.8) 128 (99.2) 275 (98.9)
African-American 2 (2.8) 3 (1.3) 0 (0.0) 0 (0.0)
Asian 0 (0.0) 1 (0.45) 0 (0.0) 0 (0.0)
Hispanic 1 (1.4) 2 (0.89) 0 (0.0) 0 (0.0)
Other 4 (5.6) 8 (3.6) 1 (0.78) 3 (1.1)
Packyears at diagnosis2, mean (SD) 30.2 (22.3) 27.6 (23.1) 0.49 30.9 (19.8) 26.9 (19.0) 0.14
Alcohol use at diagnosis (g), mean (SD) 6.3 (9.3) 6.1 (10.8) 0.86 16.1 (19.4) 13.2 (15.2) 0.12
Smoking status at diagnosis, n (%) 0.12 0.81
Never 22 (29.7) 72 (31.0) 38 (31.9) 83 (32.1)
Former 37 (50.0) 127 (54.7) 67 (56.3) 143 (55.2)
Current 15 (20.3) 33 (14.2) 14 (11.8) 33 (12.7)
1 Cases and controls were matched on year of birth
2 Among cigarette smokersBMC Cancer 2006, 6:239 http://www.biomedcentral.com/1471-2407/6/239
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bladder cancer risk observed among slow NAT2 acetyla-
tors who have a decreased capacity to detoxify aromatic
amines. Our data suggest an association between the
NAT2 slow acetylation genotype and increased bladder
cancer risk in female smokers. Our findings are biological
plausible and are consistent with a recent study in Spain
[11], which found that NAT2 slow acetylators have an
increased risk of bladder cancer that was stronger for ciga-
rette smokers compared to never smokers. NAT1 poly-
morphisms may also affect individual bladder cancer risk
by interacting with cigarette smoking. Our findings do not
support an association between the NAT1  polymor-
phisms, cigarette smoking, and bladder cancer; however
we had little power to detect such an association. Addi-
tional studies that have assessed the relationship between
NAT1*10 allele and bladder cancer risk have been incon-
sistent with some studies observing an increased risk
[17,20], a decreased risk [15], or no association
[11,16,18,19]. Larger epidemiological studies are required
to clarify the relationship between bladder cancer risk and
the NAT1*10 allele.
We observed no significant associations with the GSTM1
polymorphism and bladder cancer risk, which is in con-
trast with previous findings [11,23]. The potential role of
the GSTT1 polymorphism on bladder cancer susceptibil-
ity is less certain. Studies that have addressed the role of
GSTT1  polymorphism and bladder cancer have been
inconsistent. Of the published studies, some suggest an
increased risk [19,31,34,35] with the GSTT1 null geno-
type, others no association [11,29,30], and only one sug-
gests a decreased risk [24]. We observed no significant
association with the GSTT1 polymorphism and bladder
cancer risk.
The strengths of our study include the prospective design
and the detailed collection of exposure information (i.e.
cigarette smoking) prior to bladder cancer diagnosis. We
were also able to formally assess and test gene-environ-
ment interactions. However, our study has a small sample
size resulting in low power to detect minor to modest gen-
otype-disease associations and gene-environment interac-
tions, therefore such associations cannot be ruled out.
Conclusion
In summary, our data support the prior evidence that the
GSTM1 null genotype and the NAT2 slow acetylation gen-
otype may affect an individual's bladder cancer risk.
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